Company is blamed for early halt of trial into obesity treatmentBMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i1363 (Published 09 March 2016) Cite this as: BMJ 2016;352:i1363
- Jacqui Wise
Researchers have condemned companies that prematurely publicise study data, after a trial looking at the obesity treatment naltrexone-bupropion was stopped early before its cardiovascular safety could be fully established.
The US trial, published in JAMA,1 was stopped prematurely after the sponsor, Orexigen Therapeutics, released the interim data. The researchers said that, as a result, the cardiovascular safety of the treatment remained uncertain and that it would require evaluation in a new trial.
They said, “Premature release of interim data can result in inappropriate prejudgment about the benefits or risks of the studied therapy and make completion of the trial highly problematic.”
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial